First Experience With a Wireless System Incorporating Physiologic Assessments and Direct Confirmation of Digital Tablet Ingestions in Ambulatory Patients With Schizophrenia or Bipolar Disorder
Abstract
OBJECTIVE: To characterize the feasibility and safety of a wireless networked system incorporating physiologic assessments and direct confirmation of digital tablet ingestions in ambulatory patients with schizophrenia or bipolar disorder. METHOD: In this 4-week observational study conducted between May 2010 and May 2011 at 2 US academic clinical study sites, 12 adults with bipolar disorder and 16 adults with schizophrenia (all diagnosed according to DSM-IV criteria) utilized a digital health feedback system (DHFS). All subjects were on a stable regimen of oral medication. The DHFS utilized a digital tablet, consisting of an ingestion sensor that was embedded in a tablet containing nonpharmacologic excipients, which subjects coingested with their regularly prescribed medication. The formulation of this digital tablet allowed ingestion sensor separation and activation by stomach fluids after ingestion, followed by communication of a unique identifying signal from the ingestion sensor to an adhesive sensor worn on the torso, which automatically logged the date and time of each digital tablet ingestion. The wearable sensor also collected physiologic measures including activity and heart rate. The primary study objective was to compare the accuracy of DHFS in confirming digital tablet ingestion versus a method of directly observed ingestion; secondary aims included characterization of adherence and physiologic measures longitudinally in these cohorts. RESULTS: 27 of 28 subjects (96%) completed the study. The mean adherence rate was 74% (95% CI, 64%-86%), and 67% (95% CI, 55%-79%) of doses were taken within 2 hours of the prescribed dosing time. Activity consisted of 847 to 15,930 steps daily, and sleep duration ranged from 3.2 to 15.2 hours daily. For individual subjects, mean sleep disruption, defined as the amount of brief arousals and postural changes during sleep events (eg, subject sitting up during the night), was as low as 5% and as high as 43% for the entire study period. The most common adverse event was minor skin irritation that occurred at the site of the wearable sensor in 5 subjects (18%), which did not lead to early discontinuation. No adverse events occurred due to the ingestion sensor. No subjects developed worsening of psychosis attributable to use of the DHFS. Of the 27 subjects who completed the study, 19 (70%) found the DHFS concept easy to understand, 21 (78%) said they would like to receive reminders on their cell phone if they forgot to take their medications, and 24 (89%) thought the DHFS could be useful to them. CONCLUSIONS: The DHFS provided a novel means of confirming medication ingestion and tracking selected physiologic parameters, and it was generally well tolerated by patients. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01804257.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Prior clinical studies suggested this DMO can identify reasons for uncontrolled hypertension and help patients achieve blood pressure control.
“and suggested this DMO can identify reasons for uncontrolled HTN and help patients achieve BP control [16-21].”
Prior clinical studies demonstrated the accuracy, safety, and feasibility of using the DMO in patients across a range of medical conditions, including hypertension and type 2 diabetes mellitus.
“Prior clinical studies demonstrated the accuracy, safety, and feasibility of using the DMO in patients across a range of medical conditions, including HTN and type 2 diabetes mellitus (T2DM)”
The uncontrolled prior studies did not focus on disease control.
“However, these uncontrolled studies did not focus on disease control.”
Cited by
Sorted by citations
Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies
Haddad, P. M., Brain, C., & Scott, J. L. (2014) · Patient Related Outcome Measures · doi:10.2147/prom.s42735 · Cited by 587 · see citing works
“The feasibility and safety of the system was recently reported in a small study (n=28) of patients with schizophrenia or bipolar disorder over a 4-week period.(81) Because this was a feasibility study, the digital ingestion sensor was embedded in a placebo tablet and the main outcome was the accuracy of the system to…”
InfluentialKane, J. M., Kishimoto, T., & Correll, C. U. (2013) · World Psychiatry · doi:10.1002/wps.20060 · Cited by 520 · see citing works
Self-citationEmerging mHealth and eHealth interventions for serious mental illness: a review of the literature
Naslund, J. A., Marsch, L. A., McHugo, G. J., & Bartels, S. J. (2015) · Journal of Mental Health · doi:10.3109/09638237.2015.1019054 · Cited by 327 · see citing works
“…opening to monitor medication adherence (Acosta et al., 2009; Frangou et al., 2005), one involved ingestible digital tablets tracked using a wearable sensor (Kane et al., 2013), and one was a PDA delivered intervention for improving treatment adherence in bipolar disorder (Wenze et al., 2014).”
MethodBerry, N., Lobban, F., Emsley, R., & Bucci, S. (2016) · Journal of Medical Internet Research · doi:10.2196/jmir.5250 · Cited by 230 · see citing works
“…usefulness of the interventions, and were willing to recommend the intervention to others, was moderate to high (41% to 90.6%), although the majority of studies tended to report values of around 75% [40,47,52,60,66-68 , 77-79 Intervention use was also included as a measure of actual acceptability.”
InfluentialFrias, J., Virdi, N., Raja, P., Kim, Y., Savage, G., & Osterberg, L. (2017) · Journal of Medical Internet Research · doi:10.2196/jmir.7833 · Cited by 211 · see citing works
“) Prior clinical studies demonstrated the accuracy, safety, and feasibility of using the DMO in patients across a range of medical conditions, including HTN and type 2 diabetes mellitus (T2DM), and suggested this DMO can identify reasons for uncontrolled HTN and help patients achieve BP control [16-21].”
BackgroundBatra, S., Baker, R., Wang, T., Forma, F., DiBiasi, F., & Peters-Strickland, T. (2017) · Medical Devices: Evidence and Research · doi:10.2147/mder.s144158 · Cited by 169 · see citing works
“Of these, two reported the development of digital medicine systems to measure medication ingestion objectively and acquire physiological metrics.(18,36) In a 4-week observational study in patients with schizophrenia or bipolar disorder, positive detection accuracy with the DHFS was 94% when compared with directly obse…”
InfluentialDogan, E., Sander, C., Wagner, X., Hegerl, U., & Kohls, E. (2017) · Journal of Medical Internet Research · doi:10.2196/jmir.7006 · Cited by 177 · see citing works
“Among the participants who completed the study (n=27), the concept was found easy to understand by 70%, 89% reported that the system might be useful for them, and 78% indicated that they would prefer to receive reminders on their smartphones in case of forgetting to take the medications [36].”
BackgroundInfluentialBen-Zeev, D., Brian, R. M., Jonathan, G., Razzano, L., Pashka, N., Carpenter-Song, E., Drake, R. E., & Scherer, E. A. (2018) · Psychiatric Services · doi:10.1176/appi.ps.201800063 · Cited by 173 · see citing works
Medication nonadherence in bipolar disorder: a narrative review
Jawad, I., Watson, S., Haddad, P. M., Talbot, P. S., & McAllister-Williams, H. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125318804364 · Cited by 176 · see citing works
Ethical perspectives on recommending digital technology for patients with mental illness
Bauer, M., Glenn, T., Monteith, S., Bauer, R., Whybrow, P. C., & Geddes, J. R. (2017) · International Journal of Bipolar Disorders · doi:10.1186/s40345-017-0073-9 · Cited by 132 · see citing works
“…software) should deceive patients into thinking they are interacting with a human (Whitby 2014), the coming of medications with sensors for adherence monitoring (Kane et al. 2013), the monitoring of people with dementia (Niemeijer et al. 2011), and the evaluation of long-term clinical value.”
BackgroundCorrell, C. U., Solmi, M., Cortese, S., D, M. F. M., Højlund, M., KRAEMER, H. C., McIntyre, R. S., Pine, D. S., Schneider, L. S. S., & Kane, J. M. (2023) · World Psychiatry · doi:10.1002/wps.21056 · Cited by 111 · see citing works
Self-citationGlenn, T., & Monteith, S. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0523-3 · Cited by 104 · see citing works
Steinkamp, J., Goldblatt, N. P., Borodovsky, J. T., LaVertu, A. E., Kronish, I. M., Marsch, L. A., & Schuman‐Olivier, Z. (2018) · JMIR Mental Health · doi:10.2196/12493 · Cited by 106 · see citing works
“Multiple studies (n=31) explicitly mentioned such systems [40,42,44-46,49,51,53,63,65,91,93,95,104,105, 107,108,111,112,114,116,118-120,123,125,138,139,144,145,147], which fell under 3 major categories (not mutually exclusive): “portal” real-time monitoring (n=15), periodic reporting (n=9), and alerts (n=16).”
InfluentialAdvancing the Science and Practice of Medication Adherence
Stirratt, M., Curtis, J., Danila, M. I., Hansen, R. A., Miller, M. J., & Gakumo, C. (2018) · Journal of general internal medicine · doi:10.1007/s11606-017-4198-4 · Cited by 77 · see citing works
Smartphone-Based Tracking of Sleep in Depression, Anxiety, and Psychotic Disorders
Aledavood, T., Torous, J. B., Triana, A. M., Naslund, J. A., Onnela, J.-P. “., & Keshavan, M. S. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1043-y · Cited by 91 · see citing works
Tackling nonadherence in psychiatric disorders: current opinion
Farooq, S., & Naeem, F. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s40777 · Cited by 75 · see citing works
“A pilot study showed that this approach was feasible and acceptable to patients, as 27 of 28 subjects (96%) completed the study and the mean adherence rate was 74%.(15) All these methods have their limitations.”
Peters-Strickland, T., Pestreich, L. K., Hatch, A., Rohatagi, S., Baker, R. A., Docherty, J. P., Markovtsova, L., Raja, P., Weiden, P. J., & Walling, D. P. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s116029 · Cited by 72 · see citing works
“A novel digital medicine system (DMS) has been developed for patients with serious mental illness to objectively measure and report ingestion of aripiprazole, an atypical antipsychotic.(15) Aripiprazole is indicated in adults for the”
Utilizing an Ingestible Biosensor to Assess Real-Time Medication Adherence
Chai, P. R., Castillo‐Mancilla, J., Buffkin, E., Darling, C. E., Rosen, R. K., Horvath, K. J., Boudreaux, E. D., Robbins, G. K., Hibberd, P. L., & Boyer, E. W. (2015) · Journal of Medical Toxicology · doi:10.1007/s13181-015-0494-8 · Cited by 70 · see citing works
“To date, clinical trials using digital pills have not reported retention in the gastrointestinal tract of ingested biosensors [8, 19].”
BackgroundPsychiatry in the Digital Age: A Blessing or a Curse?
Roth, C. B., Papassotiropoulos, A., Brühl, A. B., Lang, U. E., & Huber, C. G. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18168302 · Cited by 71 · see citing works
“In one of those studies, the ingestible sensor was embedded within tablets containing a placebo [138].”
BackgroundInfluentialA comparison of passive and active estimates of sleep in a cohort with schizophrenia
Staples, P. C., Torous, J. B., Barnett, I., Carlson, K. W., Sandoval, L. R., Keshavan, M. S., & Onnela, J.-P. “. (2017) · Schizophrenia · doi:10.1038/s41537-017-0038-0 · Cited by 62 · see citing works
Digital Technologies for Schizophrenia Management: A Descriptive Review
Chivilgina, O., Elger, B. S., & Jotterand, F. (2021) · Science and Engineering Ethics · doi:10.1007/s11948-021-00302-z · Cited by 63 · see citing works
“Another example of compulsory technology is digital pills that require the patient to wear a sensor that confirms drug ingestion (Kane et al., 2013; Peters-Strickland et al., 2016; Rohatagi et al., 2016).”
BackgroundDigital Pills with Ingestible Sensors: Patent Landscape Analysis
Litvinova, O., Klager, E., Tzvetkov, N. T., Kimberger, O., Kletečka-Pulker, M., Willschke, H., & Atanasov, A. G. (2022) · Pharmaceuticals · doi:10.3390/ph15081025 · Cited by 58 · see citing works
“The effectiveness and safety of the above inventions of Proteus Digital Health were studied in clinical trials: NCT01804257 in patients (n = 28) with bipolar disorder or schizophrenia [44]; NCT03568500 in patients (n = 44) with schizophrenia, schizoaffective disorder, or first episode psychosis [45]; and NCT02091882 i…”
BackgroundMedication Nonadherence, “Professional Subjects,” and Apparent Placebo Responders
McCann, D. J., Petry, N. M., Bresell, A., Isacsson, E., Wilson, E., & Alexander, R. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000372 · Cited by 61 · see citing works
mHealth for schizophrenia spectrum disorders management: A systematic review
Chivilgina, O., Wangmo, T., Elger, B. S., Heinrich, T. W., & Jotterand, F. (2020) · International Journal of Social Psychiatry · doi:10.1177/0020764020933287 · Cited by 55 · see citing works
“The Abilify MyCite system is controversial, as it may be viewed as adversely impacting the patient’s autonomy (Kane et al., 2013; Peters-Strickland et al., 2016; Rohatagi et al., 2016).”
BackgroundDigital pills: a scoping review of the empirical literature and analysis of the ethical aspects
Martani, A., Geneviève, L. D., Poppe, C. J., Casonato, C., & Wangmo, T. (2020) · BMC Medical Ethics · doi:10.1186/s12910-019-0443-1 · Cited by 52 · see citing works
Monteith, S., Glenn, T., Geddes, J. R., Whybrow, P. C., & Bauer, M. (2016) · International Journal of Bipolar Disorders · doi:10.1186/s40345-016-0051-7 · Cited by 50 · see citing works
Wearable biomolecular sensing nanotechnologies in chronic disease management
Tu, J., Flynn, C. D., Yeom, J., Wu, Z., Kelley, S. O., & Gao, W. F. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-02010-2 · Cited by 52 · see citing works
Oxycodone Ingestion Patterns in Acute Fracture Pain With Digital Pills
Chai, P. R., Carreiro, S., Innes, B. J., Chapman, B. P., Schreiber, K. L., Edwards, R. R., Carrico, A. W., & Boyer, E. W. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000002574 · Cited by 48 · see citing works
Robinson, D. G., Schooler, N. R., Rosenheck, R. A., Lin, H., Sint, K., Marcy, P., & Kane, J. M. (2019) · Psychiatric Services · doi:10.1176/appi.ps.201800511 · Cited by 49 · see citing works
Self-citationIngestible Biosensors for Real-Time Medical Adherence Monitoring: MyTMed
Chai, P. R., Rosen, R. K., & Boyer, E. W. (2016) · Hawaii International Conference on System Sciences (HICSS) · doi:10.1109/hicss.2016.426 · Cited by 47 · see citing works
“[28, 29] Second, 96% of patients with schizophrenia or bipolar disorder successfully completed a pilot study utilizing an ingestible biosensor administered in conjunction with antipsychotic medications.[30] Third, deployment of wearable biosensors has been accepted and successful among patients with a history of cocai…”
BackgroundIngestible Sensors and Medication Adherence: Focus on Use in Serious Mental Illness
Alipour, A., Gabrielson, S. W., & Patel, P. B. (2020) · Pharmacy · doi:10.3390/pharmacy8020103 · Cited by 45 · see citing works
“The ingestible sensor is activated after being swallowed once it interacts with stomach fluid [22,27].”
BackgroundInfluentialBrowne, S. H., Behzadi, Y., & Littlewort, G. C. (2015) · JMIR mhealth and uhealth · doi:10.2196/mhealth.4292 · Cited by 38 · see citing works
Swallowing a Spy — The Potential Uses of Digital Adherence Monitoring
Rosenbaum, L. R. (2018) · New England Journal of Medicine · doi:10.1056/nejmp1716206 · Cited by 37 · see citing works
Digitizing Medicines for Remote Capture of Oral Medication Adherence Using Co‐encapsulation
Browne, S., Peloquin, C. A., Santillo, F., Haubrich, R., Muttera, L., Möser, K., Savage, G., Benson, C., & Blaschke, T. F. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.760 · Cited by 33 · see citing works
“Early studies using the DHFS were performed using the IS embedded in a small white excipient tablet (see Figures 1a and 2) swallowed in close succession by, but separately from, the medication of interest (23-26).”
MethodOptimization of a Digital Medicine System in Psychiatry
Rohatagi, S., Profit, D., Hatch, A., Zhao, C. Y., Docherty, J. P., & Peters-Strickland, T. S. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m10693 · Cited by 32 · see citing works
Kopelowicz, A. J., Baker, R. A., Zhao, C. Y., Brewer, C., Lawson, E., & Peters-Strickland, T. S. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s143091 · Cited by 28 · see citing works
Programmable “Semismart” Sensor: Relevance to Monitoring Antipsychotics
Kim, E., Chocron, S. E., Ben‐Yoav, H., Winkler, T. E., Liu, Y., Glassman, M., Wolfram, C., Kelly, D. L., Reza Ghodssi, A., & Payne, G. F. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201403783 · Cited by 25 · see citing works
Estimating longitudinal depressive symptoms from smartphone data in a transdiagnostic cohort
Pellegrini, A. M., Huang, E. J., Staples, P. C., Hart, K. L., Lorme, J. M., Brown, H. E., Perlis, R. H., & Onnela, J.-P. “. (2022) · Brain and Behavior · doi:10.1002/brb3.2077 · Cited by 22 · see citing works
“…Wang et al., 2016) and other electronic devices (De Choudhury et al., 2013; Dickerson et al., 2011; Gulbahce et al., 2012; Jashinsky et al., 2014; Kane et al., 2013; Kappeler-Setz et al., 2013; Katikalapudi et al., 2012; Matic et al., 2012; McIntyre et al., 2009; Minassian et al., 2010; Roh et…”
BackgroundSelf-citationDeveloping a Digital Medicine System in Psychiatry: Ingestion Detection Rate and Latency Period
Profit, D., Rohatagi, S., Zhao, C., Hatch, A., Docherty, J. P., & Peters-Strickland, T. S. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m10643 · Cited by 24 · see citing works
Assessment of adherence to oral antipsychotic medications: What has changed over the past decade?
Velligan, D. I., Maples, N. J., Pokorny, J. J., & Wright, C. F. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.11.022 · Cited by 25 · see citing works
Santé digitale : promesses, défis et craintes. Une revue de la littérature
Carral, M. D. R., Roux, P., Bruchez, C., & Santiago-Delefosse, M. J. (2016) · Pratiques Psychologiques · doi:10.1016/j.prps.2016.06.004 · Cited by 21 · see citing works
Hurtado‐de‐Mendoza, A., Cabling, M. L., & Sheppard, V. B. (2015) · Nursing Inquiry · doi:10.1111/nin.12101 · Cited by 21 · see citing works
Carreiro, S., Chai, P. R., Carey, J., Chapman, B. P., & Boyer, E. W. (2017) · Journal of Medical Toxicology · doi:10.1007/s13181-017-0611-y · Cited by 19 · see citing works
Review of glaucoma medication adherence monitoring in the digital health era
Erras, A., Shahrvini, B., Weinreb, R. N., & Baxter, S. L. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-317918 · Cited by 19 · see citing works
Kamal, S., Rosen, M. I., Lazar, C. M., Siqueiros, L., Wang, Y., Daar, E. S., & Liu, H. (2020) · AIDS Research and Treatment · doi:10.1155/2020/1098109 · Cited by 17 · see citing works
Miller, M., Raugh, I. M., Strauss, G. P., & Harvey, P. D. (2022) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2022.100047 · Cited by 15 · see citing works
Kim, E., Liu, Y., Ben‐Yoav, H., Winkler, T. E., Yan, K., Shi, X., Shen, J., Kelly, D. L., Reza Ghodssi, A., Bentley, W. E., et al. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201600516 · Cited by 17 · see citing works
Toward digital-based interventions for medication adherence and safety
Haga, S. B. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1764935 · Cited by 18 · see citing works
“In 2013, the first reports demonstrating the feasibility, safety, and effectiveness of ingestible sensors were published [80 – 82].”
BackgroundDigital Interventions for the Rehabilitation of First-Episode Psychosis: An Integrated Perspective
Vignapiano, A., Monaco, F., Panarello, E., Landi, S., Gruttola, B. D., Malvone, R., Martiadis, V., Raffone, F., Marenna, A., Pontillo, M., et al. (2025) · Brain Sciences · doi:10.3390/brainsci15010080 · Cited by 17 · see citing works
“Specifically, these studies have demonstrated good acceptance and sustainable use of the Digital Medicine System (DMS) within the general patient population, suggesting that this approach may represent an innovative strategy for objectively monitoring the intake of antipsychotic medications [13,14].”
Evolution of the digital biomarker ecosystem
Wright, J. M., Regele, O. B., Kourtis, L. C., Pszenny, S. M., Sirkar, R., Kovalchick, C., & Jones, G. B. (2017) · Digital Medicine · doi:10.4103/digm.digm_35_17 · Cited by 17 · see citing works
“Data are transmitted from the sensor to a receiver placed on the patient torso giving real-time data on drug movement in addition to other biomarkers such as heart rate and activity.[53] These studies have evolved to comprise what are referred to as MEMS and have been demonstrated clinically in central nervous system…”
BackgroundFowler, J. C., Cope, N., Knights, J., Fang, H., Skubiak, T., Shergill, S. S., Phiri, P., Rathod, S., & Peters-Strickland, T. S. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s290793 · Cited by 16 · see citing works
Xu, D. R., Gong, W., Gloyd, S., Caine, E. D., Simoni, J. M., Hughes, J. P., Xiao, S., He, W., Dai, B., Lin, M., et al. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.05.014 · Cited by 16 · see citing works
“However, although some studies assessed adherence in schizophrenia in developing countries (Farooq and Naeem, 2014; Farooq et al., 2011; Kane et al., 2013), there is lack of efforts to validate the various adherencemeasures in those settings.”
Wu, T., Xiao, X., Yan, S., Fang, Y., Wang, M., Zu, F., Zhang, Y., & Qian, R. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-071984 · Cited by 14 · see citing works
Human factors evaluation of a novel digital medicine system in psychiatry
Peters-Strickland, T. S., Hatch, A., Adenwala, A., Atkinson, K., & Bartfeld, B. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s157102 · Cited by 14 · see citing works
Can a digital medicine system improve adherence to antipsychotic treatment?
Papola, D., Gastaldon, C., & Ostuzzi, G. (2018) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796018000082 · Cited by 14 · see citing works
“The first is an observational pilot investigation that enrolled 28 patients with schizophrenia or bipolar disorder and demonstrated that the networked DMS yielded high detection accuracy when compared with directly observed ingestion, and was well tolerated and accepted by patients (Kane et al. 2013).”
BackgroundA scoping review of the patient experience with wearable technology
Hoff, T. J., Kitsakos, A., & Silva, J. (2024) · Digital Health · doi:10.1177/20552076241308439 · Cited by 14 · see citing works
Technology-based interventions in health care
Kane, J. M. (2014) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796014000444 · Cited by 13 · see citing works
“The new digital health technologies such as the ‘ digital health feedback system ’ (Kane et al. 2013) offers tremendous advantages.”
BackgroundSelf-citationHurtado‐de‐Mendoza, A., Cabling, M. L., Dilawari, A. A., Turner, J. W., Fernández, N. C., Henderson, A., Zhu, Q., Gómez‐Trillos, S., & Sheppard, V. B. (2018) · Health and Technology · doi:10.1007/s12553-018-0267-x · Cited by 11 · see citing works
Machine Learning for Mental Health: Applications, Challenges, and the Clinician's Role
Singhal, S., Cooke, D. L., Villareal, R. I., Stoddard, J., Lin, C., & Dempsey, A. G. (2024) · Current Psychiatry Reports · doi:10.1007/s11920-024-01561-w · Cited by 12 · see citing works
“Sleep monitoring has also provided insights into conditions like depression, bipolar disorder, and schizophrenia, helping clinicians understand symptoms and guide treatment [43–45].”
Orsolini, L., Appignanesi, C., Pompili, S., & Volpe, U. (2022) · International Review of Psychiatry · doi:10.1080/09540261.2022.2118521 · Cited by 12 · see citing works
“The application is also able to send reminders to the patient to take medication (Kane et al., 2013).”
BackgroundShafrin, J. T., Schwartz, T., Lakdawalla, D. N., & Forma, F. M. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.11.1285 · Cited by 10 · see citing works
“More recently, a new digital medicine system designed to measure medication ingestion through a sensor embedded in a medication tablet is being developed.(6,13) When the tablet reaches the stomach, it signals a wearable sensor, which in turn communicates the ingestion to a smartphone application and eventually the pat…”
BackgroundMethodCarral, M. D. R., Roux, P., Bruchez, C., & Santiago-Delefosse, M. J. (2016) · International Journal of Psychological Studies · doi:10.5539/ijps.v8n4p26 · Cited by 5 · see citing works
Use and Effectiveness of Digital Adherence Tools
Alharbi, N. A., & Alkhawaji, Y. A. (2023) · Saudi Journal of Medical and Pharmaceutical Sciences · doi:10.36348/sjmps.2023.v09i03.003 · Cited by 3 · see citing works
The role of wirelessly observed therapy in improving treatment adherence
Kumar, K., Loebinger, M. R., & Ghafur, S. (2022) · Future Healthcare Journal · doi:10.7861/fhj.2021-0165 · Cited by 3 · see citing works
Lessons Learned and Looking Forward With Pharmacy Education
Clauson, K. A., Aungst, T. D., Simard, R., Fox, B. I., & Breeden, E. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805362-1.00009-7 · Cited by 3 · see citing works
The Challenge of Nonadherence in Schizophrenia
Lawrence, R. E., & Dixon, L. B. (2019) · Springer eBooks · doi:10.1007/978-3-030-12665-0_4 · Cited by 3 · see citing works
Jan, M., Coppin-Renz, A., West, R., et al. (2023) · JMIR Formative Research · doi:10.2196/44768 · Cited by 2 · see citing works
“Previously published studies were not comparative and did not comment on safety across studies and wearable patch design changes [25,28,29,31-33].”
BackgroundMethodInfluentialDigital Medicines to Measure Drug Ingestion Adherence
Virdi, N. S. (2018) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-319-76593-8_7 · Cited by 2 · see citing works
Should a Psychiatrist Prescribe a Nanodrug to Help Parents Monitor a Teen's Adherence?
George, C. E. (2019) · The AMA Journal of Ethic · doi:10.1001/amajethics.2019.317 · Cited by 2 · see citing works
Multipoint Wireless Network for Complex Patient Monitoring based on Embedded Processors
Sumalan, T., Lupu, E., Arsinte, R., et al. (2017) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-319-52875-5_28 · Cited by 1 · see citing works
Wearable technology and artificial intelligence in psychiatric disorders
Sekhar, S. R. M., Raj, S., & Siddesh, G. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85854-0.00004-6 · Cited by 1 · see citing works
Insights into the Use of Digital Tools for People with Mental Health Disorders
Nash, D. B. (2021) · Population Health Management · doi:10.1089/pop.2021.29004.dbn · Cited by 1 · see citing works
“11,12 Capturing medication ingestion, collecting information, and making effective treatment choices present complex, interconnected challenges for clinicians whose patients suffer from mental disorders.”
Self-severing circuits facilitate passage of ingestible electronic sensor-guided therapeuticsPreprint
Healy, S., Abdigazy, A., Clinch, M. F., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.27.714561 · Cited by 1 · see citing works
mHealth and Pharmacy in Health Care
Prasad, A., Sorber, J. M., Stablein, T., Anthony, D. L., & Kotz, D. F. (2014) · CRC Press eBooks · doi:10.1201/b17724-34
mHealth and Pharmacy in Health Care
Clauson, K. A., Hajar, Z., Caballero, J., & Ownby, R. L. (2014) · CRC Press eBooks · doi:10.1201/b17724-43
Abilify MyCite® ist ein wesentlicher Fortschritt für das Adhärenzproblem – Pro
Heres, S. (2018) · Psychiatrische Praxis · doi:10.1055/a-0652-5852
“Die neuartige Messmethode darf im Therapiekonzept nicht in Form eines Sanktionsmechanismus missbraucht werden.”
BackgroundInfluentialIncreasing Psychiatric Treatment Engagement and Adherence in the College Population
Bardin, A., Cheney, B., & Braider, L. (2019) · Springer eBooks · doi:10.1007/978-3-030-12665-0_5 · Cited by 1 · see citing works
Hoffman, J. E., ROSS, R. W., Hatch, A., & Docherty, J. P. (2018) · doi:10.2196/preprints.9807
Le trouble bipolaire de type I
Romier, A., & Geoffroy, P. A. (2023) · Elsevier eBooks · doi:10.1016/b978-2-294-77180-4.00006-8
Digital and Biomarker‐Based Monitoring for Schizophrenia‐Treatment Adherence
Inshutiyimana, S., Rana, K. R., Aleu, M. M., Bwalya, N., Nsengimana, B., & Kipkurui, O. (2026) · Neuropsychopharmacology Reports · doi:10.1002/npr2.70156
“The patch also records additional physiological data such as heart rate, body position, and activity levels [20].”
Patch nonwear accounts for more than half of apparent nonadherence in a digital medicine systemPreprint
Byun, A. J. S., Chen, D., Notsu, H., Li, S., Lisowski, V., Lane, E., Ryan, S., & Torous, J. B. (2026) · medRxiv · doi:10.64898/2026.09.21.26363541
- Authors
- Kane, J. M., Perlis, R. H., DiCarlo, L. A., Au-Yeung, K., Duong, J., & Petrides, G.
- Affiliations
- Zucker Hillside Hospital (US)
- Corresponding author
- DiCarlo, Lorenzo A.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2013-06-15
- Volume
- 74
- Issue
- 06
- Pages
- e533-e540
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2083132149
- Cited by
- 81
- References
- 0
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 2 · 2023: 5 · 2022: 6 · 2021: 5 · 2020: 5 · 2019: 6 · 2018: 11 · 2017: 13 · 2016: 10 · 2015: 6 · 2014: 6 · 2013: 1
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- medication adherence, digital tablets, schizophrenia, bipolar disorder, wearable sensors, heart rate monitoring, physical activity, sleep disruption, outpatients, feasibility and safety, wireless monitoring system, antipsychotic drugs
- MeSH terms
- Adult, Bipolar Disorder, Female, Heart Rate, Humans, Male, Middle Aged, Monitoring, Physiologic, Motor Activity, Pilot Projects, Schizophrenia, Schizophrenic Psychology, Sleep, Tablets, Telemetry, Patient Satisfaction, Medication Adherence, Wireless Technology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
